1026598-40-2

Upstream product

• 156881-63-9 (R)-2-((tertbutoxycarbonyl)amino)-2-cyclopentylacetic acid 
• 1738-77-8 L-leucine benzyl ester p-toluenesulfonate 
• 177914-20-4 (S)-2-((R)-2-tert-Butoxycarbonylamino-2-cyclopentyl-acetylamino)-4-methyl-pentanoic acid benzyl ester 

Downstream Products

• 161253-78-7 (S)-2-{(R)-2-[((S)-1-{(R)-2-[(R)-2-Benzyloxycarbonylamino-3-(2-methyl-1H-indol-3-yl)-propionylamino]-3-methoxycarbonyl-propionyl}-pyrrolidine-2-carbonyl)-amino]-2-cyclopentyl-acetylamino}-4-methyl-pentanoic acid benzyl ester 
• 161253-77-6 (S)-2-((R)-2-{[(S)-1-((R)-2-tert-Butoxycarbonylamino-3-methoxycarbonyl-propionyl)-pyrrolidine-2-carbonyl]-amino}-2-cyclopentyl-acetylamino)-4-methyl-pentanoic acid benzyl ester 
• 161253-84-5 (S)-2-{[(R)-((S)-1-Benzyloxycarbonyl-3-methyl-butylcarbamoyl)-cyclopentyl-methyl]-carbamoyl}-pyrrolidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Synthesis and structure-activity relationships of 2-substituted D-tryptophan-containing peptidic endothelin receptor antagonists: Importance of the C-2 substituent of the D-tryptophan residue for endothelin A and B receptor subtype selectivity

Continuing studies on modifications of potent cyclic pentapeptide endothelin (ET) receptor antagonists, represented by BQ-123, and potent linear tripeptide derivative ET receptor antagonists, represented by BQ-788, are described herein. The introduction o